TY  - JOUR
A1  - Krakow, Sören
A1  - Crescimone, Marie L.
A1  - Bartels, Charlotte
A1  - Wiegering, Verena
A1  - Eyrich, Matthias
A1  - Schlegel, Paul G.
A1  - Wölfl, Matthias
T1  - Re-expression of CD14 in response to a combined IL-10/TLR stimulus defines monocyte-derived cells with an immunoregulatory phenotype
JF  - Frontiers in Immunology
N2  - Interleukin 10 is a central regulator of the antigen-presenting function of myeloid cells. It exerts immunomodulatory effects in vivo and induces a regulatory phenotype in monocyte-derived cells in vitro. We analyzed phenotype and function of monocytic cells in vitro in relation to the cytokine milieu and the timing of TLR-based activation. In GM-CSF/IL-4 cultured human monocytic cells, we identified two, mutually exclusive cell populations arising from undifferentiated cells: CD83\(^+\) fully activated dendritic cells and CD14\(^+\) macrophage like cells. Re-expression of CD14 occurs primarily after a sequential trigger with a TLR signal following IL-10 preincubation. This cell population with re-expressed CD14 greatly differs in phenotype and function from the CD83+ cells. Detailed analysis of individual subpopulations reveals that exogenous IL-10 is critical for inducing the shift toward the CD14\(^+\) population, but does not affect individual changes in marker expression or cell function in most cases. Thus, plasticity of CD14 expression, defining a subset of immunoregulatory cells, is highly relevant for the composition of cellular products (such as DC vaccines) as it affects the function of the total product.
KW  - regulatory dendritic cells
KW  - MDSC
KW  - monocyte-derived DC
KW  - IL-10
KW  - macrophages
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201537
VL  - 10
IS  - 1484
ER  - 
TY  - JOUR
A1  - Hagemann, Carsten
A1  - Neuhaus, Nikolas
A1  - Dahlmann, Mathias
A1  - Kessler, Almuth F.
A1  - Kobelt, Dennis
A1  - Herrmann, Pia
A1  - Eyrich, Matthias
A1  - Freitag, Benjamin
A1  - Linsenmann, Thomas
A1  - Monoranu, Camelia M.
A1  - Ernestus, Ralf-Ingo
A1  - Löhr, Mario
A1  - Stein, Ulrike
T1  - Circulating MACC1 transcripts in glioblastoma patients predict prognosis and treatment response
JF  - Cancers
N2  - Glioblastoma multiforme is the most aggressive primary brain tumor of adults, but lacksreliable and liquid biomarkers. We evaluated circulating plasma transcripts of metastasis-associatedin colon cancer-1 (MACC1), a prognostic biomarker for solid cancer entities, for prediction of clinicaloutcome and therapy response in glioblastomas.  MACC1 transcripts were significantly higher inpatients compared to controls.  Low MACC1 levels clustered together with other prognosticallyfavorable markers.  It was associated with patients’ prognosis in conjunction with the isocitratedehydrogenase (IDH) mutation status: IDH1 R132H mutation and low MACC1 was most favorable(median overall survival (OS) not yet reached), IDH1 wildtype and high MACC1 was worst (medianOS 8.1 months), while IDH1 wildtype and low MACC1 was intermediate (median OS 9.1 months).No patients displayed IDH1 R132H mutation and high MACC1. Patients with low MACC1 levelsreceiving standard therapy survived longer (median OS 22.6 months) than patients with high MACC1levels (median OS 8.1 months).   Patients not receiving the standard regimen showed the worstprognosis, independent of MACC1 levels (low: 6.8 months, high: 4.4 months). Addition of circulatingMACC1 transcript levels to the existing prognostic workup may improve the accuracy of outcomeprediction and help define more precise risk categories of glioblastoma patients.
KW  - metastasis-associated in colon cancer 1 (MACC1)
KW  - glioblastoma multiforme
KW  - liquid biopsy
KW  - therapy response
KW  - prognostic marker
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-197327
SN  - 2072-6694
VL  - 11
IS  - 6
ER  -